X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (140) 140
humans (135) 135
infliximab (120) 120
gastroenterology & hepatology (105) 105
crohns-disease (96) 96
female (86) 86
male (86) 86
serum infliximab (81) 81
adult (70) 70
antibodies (60) 60
inflammatory bowel disease (60) 60
crohn's disease (59) 59
crohn disease - drug therapy (54) 54
inflammatory-bowel-disease (53) 53
middle aged (53) 53
adalimumab (52) 52
treatment outcome (51) 51
inflammatory bowel diseases - drug therapy (47) 47
immunogenicity (45) 45
therapy (45) 45
tumor necrosis factor-alpha - antagonists & inhibitors (43) 43
ulcerative colitis (43) 43
pharmacokinetics (37) 37
serum (36) 36
young adult (35) 35
gastrointestinal agents - therapeutic use (33) 33
infliximab - therapeutic use (33) 33
trough levels (33) 33
antibodies - blood (32) 32
antibodies, monoclonal - therapeutic use (32) 32
dose intensification (32) 32
pharmacology & pharmacy (30) 30
ulcerative-colitis (30) 30
adolescent (29) 29
drug monitoring (28) 28
efficacy (28) 28
therapeutic drug monitoring (28) 28
c-reactive protein (27) 27
clinical-response (27) 27
monoclonal antibodies (27) 27
care and treatment (26) 26
retrospective studies (26) 26
association (25) 25
crohn disease - blood (25) 25
antibodies, monoclonal - blood (24) 24
prospective studies (24) 24
rheumatoid arthritis (24) 24
aged (23) 23
colitis, ulcerative - drug therapy (23) 23
severity of illness index (23) 23
drug monitoring - methods (22) 22
patients (22) 22
remission (22) 22
immunoglobulins (21) 21
infliximab - blood (21) 21
maintenance therapy (21) 21
rheumatoid-arthritis (21) 21
tumor necrosis factor-α (21) 21
inflammatory bowel diseases (20) 20
adalimumab - therapeutic use (19) 19
enzyme-linked immunosorbent assay (19) 19
ibd (19) 19
infliximab - immunology (19) 19
remission induction (19) 19
antibodies, monoclonal - pharmacokinetics (18) 18
maintenance (18) 18
tumor necrosis factor (18) 18
anti-inflammatory agents - therapeutic use (17) 17
gastrointestinal diseases (17) 17
rheumatology (17) 17
antibodies, monoclonal - immunology (16) 16
crohn’s disease (16) 16
dose-response relationship, drug (16) 16
drug therapy (16) 16
infliximab - administration & dosage (16) 16
infliximab trough levels (16) 16
tumor necrosis factor-tnf (16) 16
viral antibodies (16) 16
biomarkers - blood (15) 15
child (15) 15
gastrointestinal agents - administration & dosage (15) 15
gastrointestinal agents - pharmacokinetics (15) 15
prognosis (15) 15
research (15) 15
analysis (14) 14
c-reactive protein - metabolism (14) 14
crohn disease - immunology (14) 14
gastrointestinal agents - blood (14) 14
infliximab - pharmacokinetics (14) 14
anti-tnf (13) 13
antirheumatic agents - therapeutic use (13) 13
arthritis, rheumatoid - drug therapy (13) 13
cross-sectional studies (13) 13
dosage and administration (13) 13
inflammatory bowel diseases - immunology (13) 13
musculoskeletal diseases (13) 13
outcomes (13) 13
abridged index medicus (12) 12
antidrug antibodies (12) 12
certolizumab pegol (12) 12
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Journal Article
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 02/2019, Volume 31, Issue 2, pp. 187 - 191
BACKGROUNDInfliximab trough levels (IFX-TLs) and antibodies to infliximab (ATIs) have been suggested as useful markers for the optimization of treatment in... 
Crohn's disease | trough levels | ulcerative colitis | biomarkers | infliximab | C-REACTIVE PROTEIN | ANTIBODIES | MANAGEMENT | CROHNS-DISEASE | EFFICACY | SERUM INFLIXIMAB | IBD | COMBINATION | INDUCTION THERAPY | GASTROENTEROLOGY & HEPATOLOGY | ASSOCIATION | Inflammatory bowel diseases | C-reactive protein | Infliximab | Dosage and administration | Research | Biological markers | Drug therapy
Journal Article
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 03/2016, Volume 28, Issue 3, pp. 271 - 276
INTRODUCTIONOptimal trough levels of the anti-tumour necrosis factor agents, infliximab and adalimumab, are correlated with clinical remission. Obesity... 
Inflammatory bowel disease | Infliximab | Crohn's disease | Adalimumab | BMI | Smoking | Ulcerative colitis | NUCLEOTIDE LEVELS | CROHNS-DISEASE | SERUM INFLIXIMAB | infliximab | inflammatory bowel disease | adalimumab | PROSPECTIVE COHORT | OBESITY | INFLAMMATORY-BOWEL-DISEASE | PHARMACOKINETICS | smoking | BODY-MASS INDEX | ulcerative colitis | TNF MONOCLONAL-ANTIBODIES | GASTROENTEROLOGY & HEPATOLOGY | ASSOCIATION | Prospective Studies | Infliximab - analysis | Humans | Middle Aged | Anti-Inflammatory Agents - immunology | England | Male | Colitis, Ulcerative - immunology | Obesity - blood | Infliximab - pharmacokinetics | Young Adult | C-Reactive Protein - metabolism | Adalimumab - blood | Crohn Disease - diagnosis | Adult | Anti-Inflammatory Agents - administration & dosage | Anti-Inflammatory Agents - pharmacokinetics | Female | Obesity - diagnosis | Colitis, Ulcerative - drug therapy | Infliximab - blood | Body Mass Index | Cross-Sectional Studies | Inflammation Mediators - blood | Obesity - physiopathology | Biomarkers - blood | Colitis, Ulcerative - blood | Infliximab - immunology | Crohn Disease - immunology | Anti-Inflammatory Agents - blood | Adalimumab - administration & dosage | Colitis, Ulcerative - diagnosis | Crohn Disease - blood | Crohn Disease - drug therapy | Antibodies - blood | Drug Monitoring | Tumor Necrosis Factor-alpha - antagonists & inhibitors
Journal Article
Journal Article
Analytical and bioanalytical chemistry, ISSN 1618-2642, 2013, Volume 405, Issue 23, pp. 7367 - 7375
Monitoring levels of biologicals against tumor necrosis factor (TNF) has been suggested to improve therapeutic outcomes in inflammatory bowel diseases (IBDs).... 
Biochemistry, general | Trough level monitoring | Food Science | Laboratory Medicine | Rapid assay | Chemistry | Analytical Chemistry | Infliximab | Rheumatoid arthritis | Characterization and Evaluation of Materials | Point-of-care | Environmental Monitoring/Analysis | Crohn’s disease | Crohn's disease | ANTIBODIES | CHEMISTRY, ANALYTICAL | HUMORAL IMMUNE-RESPONSES | ANTI-TNF | CROHNS-DISEASE | EFFICACY | BIOCHEMICAL RESEARCH METHODS | SERUM | IMMUNOGENICITY | INFLAMMATORY-BOWEL-DISEASE | BIOLOGICAL THERAPIES | CLINICAL-RESPONSE | Limit of Detection | Biological Assay - standards | Arthritis, Rheumatoid - blood | Antibodies, Anti-Idiotypic - blood | Humans | Tumor Necrosis Factor-alpha - blood | Phosphorus - chemistry | Antibodies, Monoclonal - therapeutic use | Biological Assay - methods | Crohn Disease - immunology | Luminescent Measurements - methods | Feasibility Studies | Antibodies, Monoclonal - blood | Staphylococcal Protein A - chemistry | Crohn Disease - blood | Crohn Disease - drug therapy | Staining and Labeling | Protein Binding | Antibodies, Anti-Idiotypic - chemistry | Luminescent Measurements - standards | Arthritis, Rheumatoid - immunology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Chemical properties | Research | Biological assay | Identification and classification | Methods | Pharmaceutical chemistry | Immunoglobulins | Feasibility studies | Monoclonal antibodies | Labels | Assaying | Serums | Patients | Monitoring
Journal Article
Journal of Crohn's & colitis, ISSN 1873-9946, 02/2019, Volume 13, Issue 2, pp. 189 - 197
Background and Aims: Mucosal healing is an important treatment goal in Crohn's disease. We investigated the association between serum infliximab trough levels... 
THERAPEUTIC WINDOW | ANTIBODIES | SERUM INFLIXIMAB | infliximab | Crohn's disease | CHILDREN | INFLAMMATORY-BOWEL-DISEASE | DECISION-MAKING | PHARMACOKINETICS | CLINICAL-USE | GASTROENTEROLOGY & HEPATOLOGY | OPPORTUNITY | mucosal healing | REMISSION
Journal Article